Central serous chorioretinopathy associated with administration of sympathomimetic agents.
OBJECTIVE
To report central serous chorioretinopathy associated with excessive use of compounds with sympathomimetic activity.


METHODS
Observational case series.


METHODS
Four patients presented with clinical and fluorescein angiographic evidence of central serous chorioretinopathy. All patients expressed a concomitant psychogenic stress and high-dose ingestion of pseudoephedrine, oxymetazoline, or 3,4-methylenedioxymethamphetamine, all of which possess sympathomimetic properties.


RESULTS
In all cases, resolution of central serous chorioretinopathy coincided with cessation of the medication.


CONCLUSIONS
Patients afflicted with central serous chorioretinopathy should be notified about its possible association with sympathomimetic medications.
Michael
John C
JC
Retina Institute of Illinois, Niles, Illinois 60714, USA. johnmichael@aol.com
Pak
John
J
Pulido
Jose
J
de Venecia
Guillermo
G
D000328:Adult; D015862:Choroid Diseases / Q000139:chemically induced* / Q000175:diagnosis; D004809:Ephedrine / Q000009:adverse effects; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects; D009887:Ophthalmoscopy; D010109:Oxymetazoline / Q000009:adverse effects; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D013566:Sympathomimetics / Q000009:adverse effects*; D014792:Visual Acuity
D013566:Sympathomimetics; D010109:Oxymetazoline; D004809:Ephedrine; D018817:N-Methyl-3,4-methylenedioxyamphetamine